Bioventus Inc.
BVS
$8.52
$0.010.12%
NASDAQ
| 03/28/2026 | 12/31/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Revenue | 576.30M | 568.09M | 563.83M | 564.14M | 567.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 576.30M | 568.09M | 563.83M | 564.14M | 567.70M |
| Cost of Revenue | 180.43M | 179.93M | 181.80M | 182.79M | 184.80M |
| Gross Profit | 395.87M | 388.16M | 382.03M | 381.35M | 382.90M |
| SG&A Expenses | 318.80M | 313.98M | 318.01M | 320.80M | 325.87M |
| Depreciation & Amortization | 5.24M | 5.73M | 6.20M | 6.87M | 7.49M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 516.04M | 511.75M | 518.38M | 523.75M | 532.49M |
| Operating Income | 60.26M | 56.34M | 45.45M | 40.39M | 35.21M |
| Income Before Tax | 33.64M | 25.71M | 11.51M | 1.58M | -50.29M |
| Income Tax Expenses | -899.00K | -1.57M | 2.16M | 2.09M | -6.30M |
| Earnings from Continuing Operations | 34.54 | 27.27 | 9.35 | -0.50 | -43.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -6.06M | -4.54M | -1.76M | -230.00K | 10.12M |
| Net Income | 28.48M | 22.73M | 7.59M | -731.00K | -33.87M |
| EBIT | 60.26M | 56.34M | 45.45M | 40.39M | 35.21M |
| EBITDA | 100.24M | 96.98M | 85.55M | 81.37M | 77.22M |
| EPS Basic | 0.43 | 0.34 | 0.11 | -0.01 | -0.53 |
| Normalized Basic EPS | 0.25 | 0.20 | 0.12 | 0.07 | 0.16 |
| EPS Diluted | 0.41 | 0.33 | 0.11 | -0.02 | -0.53 |
| Normalized Diluted EPS | 0.24 | 0.19 | 0.11 | 0.06 | 0.16 |
| Average Basic Shares Outstanding | 267.74M | 266.45M | 264.89M | 263.22M | 260.78M |
| Average Diluted Shares Outstanding | 276.64M | 272.64M | 268.84M | 265.26M | 260.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |